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1018 Reduction of systolic and diastolic dysfunction by retrograde coronary sinus
perfusion during off-pump coronary surgery
Manuel Castella´, MD, and Gerald D. Buckberg, MD, Los Angeles, Calif
Retrograde coronary sinus perfusion during simulated off-pump coronary revascularization
diminishes systolic stunning and diastolic dysfunction. An aorticcoronary sinus shunt is a
rapid, recognized approach that can improve myocardial muscle and endothelial safety during
CABG in the beating heart.
1026 Minimally invasive technology for mitral valve surgery via left thoracotomy:
Experience with forty cases
Paul C. Saunders, MD, Eugene A. Grossi, MD, Ram Sharony, MD, Charles F. Schwartz, MD,
Greg H. Ribakove, MD, Alfred T. Culliford, MD, Julie Delianides, MSN, F. Gregory Baumann,
PhD, Aubrey C. Galloway, MD, and Stephen B. Colvin, MD, New York, NY
Advances in minimally invasive cardiac surgery technology are readily adaptable to a left-sided
minithoracotomy approach to the mitral valve. This approach, as reported in a series of 40
patients, is a safe option in complicated reoperative mitral procedures, with acceptable
perioperative morbidity and mortality.
1033 Blockade of the extracellular signal-regulated kinase pathway by U0126
attenuates neuronal damage following circulatory arrest
Deog-Gon Cho, MD, Matthew R. Mulloy, MD, Paul A. Chang, BS, Mahlon D. Johnson, MD,
PhD, Alon S. Aharon, MD, Trevor A. Robison, BS, Tamara L. Buckles, BS, Daniel W. Byrne,
MS, and Davis C. Drinkwater, Jr, MD, Nashville, Tenn, and St Louis, Mo
We evaluated the ability of an MEK1/2-specific inhibitor (U0126) to block ERK1/2 activation
and mitigate neuronal damage in piglets undergoing deep hypothermic circulatory arrest
(DHCA). Blockade by U0126 significantly decreased neuronal damage following DHCA. The
neuroprotection seen was accompanied by inhibition of phosphorylated ERK1/2 expression in
the cerebral vascular endothelium.
1041 Angiogenic pretreatment improves the efficacy of cellular cardiomyoplasty
performed with fetal cardiomyocyte implantation
Mauricio A. Retuerto, BS, Paul Schalch, MD, Gerald Patejunas, PhD, JoAnn Carbray, BS,
Naxin Liu, MD, Karyn Esser, PhD, Ronald G. Crystal, MD, and Todd K. Rosengart, MD,
Evanston and Chicago, Ill, and New York, NY
We tested the hypothesis that pretreatment of infarcted myocardium with angiogenic therapy,
followed by cell transplant, would be more effective than the application of either strategy
alone. Exercise tolerance was significantly prolonged in animals receiving AdVEGF prior to
cell implantation compared with animals receiving AdVEGF or cells alone or those receiving
AdVEGF at the time of cell implantation (P  .001). These functional data were consistent
with improvements in infarct vascularization and implanted cell survival.
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